Event Date/Time: Jul 21, 2010 End Date/Time: Jul 22, 2010
Report as Spam


With biobanking experts and leaders (and end-users) from Genentech, Pfizer, AstraZeneca, Boehringer Ingelheim, Spanish National Cancer Research Centre, Wales Cancer Bank, Chernobyl Tissue Bank (Imperial College London) and WHO discussing the critical challenges and opportunities for successful biosample management in human disease research, don't miss the world's leading biobanking conference designed for both biobanks and big pharmaceutical and biotech companies.

What's covered on the agenda?
Currently, heterogeneity in the way biobanks are managed is one of the biggest obstacles to widespread biomarker and targeted therapy development.

Listen to Pierre Hainaut from WHO discuss critical aspects of biobank design and governance, with an emphasis on overcoming key challenges for creating biobank networks for enhanced sample sharing and successful implementation of molecular biomarkers in therapeutic decision- making.
Hear Chris Womack detailing the key practical considerations for securing access to human tissue in pharma research from the experience of AstraZeneca, including ensuring appropriately skilled teams, active support of patients, focus on requirements of sample end users and fit for purpose sample quality.
Other highly current topics to have emerged from our research with key stakeholders in the biobanking and pharmaceutical industry that will be addressed at the meeting include:

Ensuring access to high quality specimens for disease research
Capturing the true value of biosamples through effective sample tracking, successful biodata annotation and developing informed consent best practice
Optimising biobanking strategies to ensuring researcher's needs are met
Achieving and maintaining sample quality
Enabling successful partnerships for effective collation of bio data
Utilising continuing technological development for efficient biobank management, including
automation, data warehousing, interoperability and risk management

This meeting has been carefully designed to bring together the key stakeholders from both the public and private sectors. That includes those who are managing or utilising biological data, working to optimize biobanking strategies to enhance drug development, and those determining how to form successful partnerships to capitalise on the enormous potential behind better use of biosamples in drug discovery and development.